BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 37629096)

  • 1. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
    Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma.
    Chen P; Yu J; Luo Q; Li J; Wang W
    BMC Gastroenterol; 2023 Nov; 23(1):382. PubMed ID: 37946148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
    Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
    Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
    Kang K; Li X; Peng Y; Zhou Y
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
    Xing F; Qin Y; Xu J; Wang W; Zhang B
    Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma.
    Xue W; Qiu K; Dong B; Guo D; Fu J; Zhu C; Niu Z
    Cancer Cell Int; 2023 Sep; 23(1):218. PubMed ID: 37759294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma.
    Yang F; Niu X; Zhou M; Li W
    Sci Rep; 2024 Jun; 14(1):14436. PubMed ID: 38910181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z; Su M; Li X; Xie J; Han F; Yao J
    BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
    Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
    Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
    Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
    Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer.
    Wu Z; Lu Z; Li L; Ma M; Long F; Wu R; Huang L; Chou J; Yang K; Zhang Y; Li X; Hu G; Zhang Y; Lin C
    Front Immunol; 2021; 12():783362. PubMed ID: 35154072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma.
    Chen D; Li Q; Xu Y; Wei Y; Li J; Zhu X; Li H; Lu Y; Liu X; Yan D
    Cancer Cell Int; 2023 Dec; 23(1):316. PubMed ID: 38066643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma.
    Xu L; Chen S; Li Q; Chen X; Xu Y; Zhou Y; Li J; Guo Z; Xing J; Chen D
    Cancer Cell Int; 2024 Jan; 24(1):30. PubMed ID: 38218909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
    Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
    Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.